HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced incidence of retinopathy of prematurity.

AbstractAIM:
To audit the prevalence of retinopathy of prematurity (ROP) in a level 2 status neonatal unit.
METHODS:
Data were collected prospectively over 9 years from September 1989 to September 1998. Preterm infants were examined according to the Royal College of Ophthalmologists' guidelines and retinopathy graded following the International Classification of ROP. ROP 3-5 was analysed using logistic regression in relation to time, and to gestational age and birth weight.
RESULTS:
383 babies were examined. Mean gestational age fell over the 9 year period (p=0.051) as did mean birth weight (p<0.001). There was a decrease in the number of infants with ROP grades 3-5 over the 9 years (p=0.045 and, when adjusted for gestational age and birth weight, the decrease in ROP 3-5 was significant (p=0.03).
CONCLUSIONS:
This study found a significant reduction in the incidence of ROP during the 9 years of the study period, despite a decrease in mean gestational age of and birth weight. The reduced incidence of ROP is attributed to improvements in ventilation techniques and overall care of the neonate, in particular the use of prenatal steroids and surfactant.
AuthorsE Rowlands, A C Ionides, S Chinn, H Mackinnon, C C Davey
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 85 Issue 8 Pg. 933-5 (Aug 2001) ISSN: 0007-1161 [Print] England
PMID11466248 (Publication Type: Journal Article)
Topics
  • Birth Weight
  • Gestational Age
  • Humans
  • Incidence
  • Infant, Newborn
  • Infant, Premature, Diseases (epidemiology, pathology)
  • Logistic Models
  • London (epidemiology)
  • Longitudinal Studies
  • Prevalence
  • Retinopathy of Prematurity (epidemiology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: